JayMarshallFeingoldMD

Pediatric Hematology & Oncology • Boca Raton, FL

chief Medical Officer ADC Therapeutics

Join to view full profile

Dr. Feingold is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Feingold's full profile

Already have an account?

Office
7001 Mallorca Crescent
Boca Raton, FL 33433
Phone+1 484-802-8711

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Pediatric Hematology/Oncology, 1988 - 1992
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Pediatrics, 1987 - 1988
Albert Einstein College of MedicineClass of 1986

Certifications & Licensure

CA State Medical License 1987 - Present
PA State Medical License 2000 - 2024
CT State Medical License 1995 - 2000
IL State Medical License 1992 - 1999

Publications & Presentations

PubMed

47 citations
Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study
Mehdi Hamadani, Graham P. Collins, Paolo Caimi, Felipe Samaniego, Alexander I. Spira
The Lancet. Haematology. 2021-06-01
208 citations
Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies
Janice P. Dutcher, Paul de Souza, David F. McDermott, Robert A. Figlin, Anna Berkenblit
Medical Oncology. 2009-02-20
28 citations
Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia.
Nitin Jain, Wendy Stock, Amer M. Zeidan, Ehab Atallah, James K. McCloskey
Blood Advances. 2020-02-11

Abstracts/Posters

Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refra...
Jay Feingold, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based CD25-Targeting Antibody Drug Conjugate, in a Phase 1 Study of Relapsed/Refractory Non-Hodgkin Lym...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Pfizer, Bayer-Backed Pyxis Ups IPO Price as Biotech's Public Run Continues UnabatedOctober 8th, 2021
Bankrolled by Pfizer and Bayer, Pyxis Files for $100M IPO to Take Cancer Drugs into the ClinicSeptember 20th, 2021
Chutes & Ladders—AltruBio Snags New CMO with Resume at Sublimity, Ardea, Amgen and AbbottSeptember 17th, 2021
Join now to see all

Professional Memberships

American Society of Hematology - ASH
Member
American Association for Cancer Research - AACR
Member
American Society of Clinical Oncology - ASCO
Member

Industry Relationships

Chief Medical Officer, ADC Therapeutics2014 - Present